Where We’re Finding Value for Biotech Investors
Most Popular - PropThink kicked off the week by revisiting Endo Health (ENDP) and brought the scoop on Rajiv De Silva’s materializing plans for the company. De Silva, … Continue Reading
Read nowSearch Results for endo health
This Week’s Top Stories in Biotech
Most Popular - Jason Napodano laid out the DRRX investment thesis. Will Pfizer re-file the Remoxy NDA? And what about Posidur? They’re both real value drivers for DRRX, … Continue Reading
Read nowOpana Story De-Emphasized, ENDP Take Out Re-Emphasized
Long Ideas - A price target reduction from RBC Capital Markets took $1.06 (or 3.4%) out of Endo Health Solutions (ENDP) Thursday, noting risks to the company’s pain … Continue Reading
Read nowMarket Noise Masks KERX’s Real Potential
Long Ideas - The spin doctors have done a great job pressuring Keryx BioPharmaceuticals (KERX) recently, pulling out all the stops to drive the stock down. Massive share … Continue Reading
Read nowENDP a Buyout Target; Valeant The Lead Suspect And Moves Quickly
Long Ideas - Reuters reported on Wednesday afternoon that, according to industry sources, Endo Health Solutions (ENDP) is in talks with potential buyers of the business. Our “Trouble … Continue Reading
Read nowENDP Clears Out The Bad News; New Money Ready To Enter
Long Ideas - Endo Health Solutions (NASDAQ:ENDP) re-established financial guidance Thursday night, re-affirming 2012’s prior outlook and, as expected, guiding expectations lower for revenue and EPS in 2013. This … Continue Reading
Read nowENDP Validates That New Opana ER Formulation Reduces Abuse; Stock Should Respond Favorably
Long Ideas - Against a backdrop of growing opioid abuse in the U.S., Endo Health Solutions (NASDAQ:ENDP) announced another step Monday night in its efforts to curb abuse … Continue Reading
Read now